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Available online 11 February 2016The Genea091 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, carrying Htt gene CAG expansion of 40 repeats, indicative of Huntington Disease. Following ICM out-
growth on inactivatedhuman feeders, karyotypewas conﬁrmed as46, XXbyCGHand STR analysis demonstrated
a female Allele pattern. The hESC line had pluripotent cell morphology, 92% of cells expressed Nanog, 97% Oct4,
79% Tra1-60 and 98% SSEA4 and gave a Pluritest pluripotency score of 38.36, Novelty of 1.35. The cell line was
negative for Mycoplasma and visible contamination.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).Resource TableDame of Stem Cell line
KGenea091 — Huntington Disease affected
(Alternate ID: SIVF091)Sestitution Genea Biocells
Person who created resource Biljana Dumevskaontact person and email biljana.dumevska@geneabiocells.com
Date archived/stock date June 2012rigin Human embryos
Stpe of resource Derived human embryonic stem cell lineb-type HD affected human pluripotent cell line
Siey marker expression Nanog, Oct4, Tra1-60, and SSEA4uthentication Identity and purity of cell line conﬁrmed
(Fig. 1 and Tables 1 and 2 below)nk to related literature
(direct URL links and
full references)(McQuade & Balachandran, 2014)
http://www.ncbi.nlm.nih.gov/pubmed/25316320formation in public
databasesNational Institutes of Health registered, NIH:
NIHhESC-14-0246
UK Stem Cell Bank registered, UKSCB: SCSC14-49thical approval Obtained from the Genea Ethics Committee on 13
September 2005 under the Australian National
Health and Medical Research Council (NHMRC)
licence 309710(B. Dumevska).
. This is an open access article underResource Detailstheate of derivationCC BY-NC-ND license (http://cMay 2012
aryotype 46, XX
x Female
luripotent YES — by Nanog, Oct4, Tra1-60, and SSEA4 staining
and Pluritest
isease status Expansion of CAG repeats (40 CAG Repeats) —
Huntington Disease (HD) affected, OMIM: 143100
erility The cell line is tested and found negative for
Mycoplasma and any visible contamination
bling lines available YES — Genea089 (XX — HD affected, NIH:
NIHhESC-14-0247), Genea090 (XX — HD
affected, NIH: NIHhESC-14-0245)Materials and methods
Cell line derivation
The zona pellucida of a blastocyst-stage human embryo was manu-
ally removed using a small blade. The embryo was bisected and plated
onto irradiated human feeders (Detroit 551 HFF — 90,000/well in 4-
well) in 20% KSR medium with 20 ng/mL FGF added fresh (Amit et al.,
2000). CGH karyotyping and STR proﬁling were performed at the ﬁrst
cryobanking step from ICM outgrowths maintained on feeders. Cells
were then enzymatically passaged as single cells in M2 pluripotent
cell maintenance medium (Genea Biocells) and CGH/karyotypingreativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
CGH analysis summary; Genea091 (passage 3) reporting a female cell line and no abnor-
malities detected.
CGH summary
Sample name Genea091p3
Date reported 16th August 2012
Hybridisation balance Balanced hybridization was observed for all
chromosomes, relative to reference DNA
Copy number change No copy number changes above 400 kb were detected
Interpretation Female cell line — no abnormalities detected
450 B. Dumevska et al. / Stem Cell Research 16 (2016) 449–451repeated, immunoﬂuorescent pluripotentmarker staining, Pluritest and
sterility testing performed.Genetic analysis
1. Comparative Genomic Hybridisation (CGH) based chromosomal
analysis: Passage 3; CGH was used to screen targeted regions of
the genome for gains and losses associated with chromosomal
imbalances such as aneuploidy, deletions and duplications. CGH
was performed using SurePrint G3 microarrays (8 × 60 K format)
which were scanned with the Agilent Scanner C and analysed
using Genomic Workbench Standard Edition 5.0 software (Agilent
Technologies).
2. DNA proﬁling: Passage 3; DNA ‘ﬁngerprinting’ was performed
using the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied
Biosystems #4322288) to provide permanent genetic identiﬁcation
of the cell lines. https://www.thermoﬁsher.com/order/catalog/
product/4322288.Table 2
STR proﬁle; Genea091 (passage 3) demonstrating female allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S31
GENEA091p3 13,15 29,31 10,11 12,14 17 6 9,11
Fig. 1. Pluripotency validation of Genea090. A) Immunoﬂuorescent staining (10×) of pluripoten
enzymatic). B) Quantitation of expression of pluripotent markers. C) Pluritest pluripotency (lePluripotency assessment
1. Immunoﬂuorescence: Passage 9 (4 on feeders, 5 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1-60 #560121 1:150; SSEA4 #560308
1:200 (all BD Pharmingen). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
2. Pluritest: Passage 8 (4 on feeders, 4 enzymatic); RNA was collected
and subjected to a Pluritest, a bioinformatic assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012).
Sterility testing
1. Mycoplasma: Passage 8 (4 on feeders, 4 enzymatic); testingwas per-
formed as per manufacturer's instructions using the MycoAlert My-
coplasma Detection Kit from LONZA
2. Microbial contamination: testingwas performed in conjunctionwith
our QC measures. Cells were thawed and cultured in 7 mL antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. A
clear solution at ~48–72 h indicated lack of bacterial, fungal or
yeast contamination. Clarity of the solution was assessed by Cell Pro-
duction Team.
Veriﬁcation and authentication
Ethics/consents
Ethics approval for the project (‘derivation of human embryonic
stem cells from embryos identiﬁed through pre-implantation genetic
diagnosis to be affected by known genetic conditions’) was obtained
from the Genea Ethics Committee on 13 September 2005. Excess ART7 D16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
11,12 17 12,13 18,19 9,11 14 10,12 22,23
t cellmarkers SSEA4 (green), Nanog (red), Oct3/4 (green) and Tra1/60 (red), (passage 9, 5
ft) and novelty (right) scores with Genea091 (passage 8, 4 enzymatic) outlined in black.
451B. Dumevska et al. / Stem Cell Research 16 (2016) 449–451embryos were fully consented for stem cell derivation by all responsible
people through an informed consent process (signed de-identiﬁed
consent form can be provided upon request). Donors have received no
payment or ﬁnancial beneﬁts for their donation. Genea091 has been de-
rived from a donated, fully commercially consented embryo, originally
created by assisted reproduction technology (ART) for the purpose of
procreation. The embryo was identiﬁed through pre-implantation
genetic diagnosis to be affected by a genetic mutation and was
declared excess to reproductive needs. Derivation was performed
under Australian National Health and Medical Research Council
(NHMRC) licence 309,710. This licence was issued to GENEA on 7 May
2007. More information about the licence can be obtained from the
NHMRC webpage at http://www.nhmrc.gov.au/health-ethics/human-
embryos-and-cloning/database-licences-authorising-use-excess-art-
embryos.
PGD analysis conclusion
Mutation; expansion of CAG (40 CAG repeats) in HTT gene. Family
tree; father has 41 repeats; inherited from his father. Huntington Dis-
ease (HD) affected.
Morphology
The derived stem cell line, Genea091, morphologically displays ad-
herent monolayer of compact cells in well-deﬁned colonies with high
nuclear to cytoplasmic ratio and prominent nucleoli.
Genetic analysis
The cell line has been karyotyped and tested by CGH, which demon-
strated 46, XX karyotype (Table 1, Supplementary Fig. 1) consistentwith original derivation and pre-implantation genetic diagnosis
(PGD). Analysis of STR markers showed Allele pattern consistent with
female genotype (Table 2, Supplementary Fig. 2).
Pluripotency
GENEA091 is pluripotent by;
1. Immunoﬂuorescence with 92% Nanog positive, 97% Oct4, 79% Tra1-
60 and 98% SSEA4 positive (Fig. 1A, quantiﬁed in 1B).
2. Pluritest with a pluripotency score of 38.36 and Novelty score of 1.35
(Fig. 1C).
Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 3).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.022.
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